CCM
EWTX icon

Cinctive Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Cinctive Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$801K – 391
2024
Q3 		$801K Buy
+30,000
New +$597K 0.04% 311

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Cinctive Capital Management's EWTX Position: Q1 2025 in Review

Cinctive Capital Management sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 14,093 shares — an estimated $376K sold.

Cinctive Capital Management first reported a position in EWTX in Q3 2024 and held it in 2 quarters. The position peaked at $1.23M in Q3 2024. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

  • Cinctive Capital Management reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cinctive Capital Management sold 14,093 Edgewise Therapeutics shares in Q1 2025, an estimated $376K.
  • Cinctive Capital Management first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 2 quarters.
  • Cinctive Capital Management's Edgewise Therapeutics position peaked at $1.23M in Q3 2024.
  • 192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on Cinctive Capital Management's 13F filing for Q1 2025, filed 15 May 2025.